Health News Releases

  • Today November 13
November 17, 2015 22:00
Gore Achieves 40 Million Implants Sold Worldwide as it Celebrates 40 Years of Performance
W. L. Gore & Associates, Inc. (Gore) today announced in conjunction with its 40th anniversary, it has sold 40 million devices worldwide. The milestones come as the company showcases its latest innovat
November 17, 2015 16:40
Time is of the Essence for Millions Living with ‘Neglected’ Lung Disease: Your Time Campaign Calls for Earlier Action in COPD
Boehringer Ingelheim today announced the launch of the Your Time campaign - a worldwide call to raise public awareness of chronic obstructive pulmonary disease (COPD) and the importance of acting now.
November 17, 2015 14:15
India’s Leading Maternity and Birthing Care Hospital Group, Cloudnine, Adopts Masimo SET® Technology to Screen Infants for CCHD
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that Cloudnine Hospital Group - a leader in providing premier quality healthcare to women and children in India - has upgraded system-wide to Mas
November 17, 2015 10:50
Pharco Pharmaceuticals Inc. Reports Ravidasvir Achieved 100% Cure Rate to Date When Combined with Sofosbuvir for HCV, Non-Cirrhotic, Genotype 4 Patients
Egypt’s leading drug manufacturer Pharco Pharmaceuticals, Inc. announced advanced results today from its Phase III clinical trial of the combination of ravidasvir with sofosbuvir for the treatment of
November 16, 2015 22:00
Replicor Discloses Continued Improvement of the Antiviral Response in Patients with HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, disclosed upd
November 16, 2015 11:50
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim today announced the presentation of new analyses of OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF) at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washin
November 16, 2015 10:00
Apira Science Inc. Expands iGrow Hair Growth System's Global Footprint Across Asia and Middle East
Apira Science, Inc. (www.apirascience.com) today announced that it has received clearance to sell and distribute the iGrow Hair Growth System (www.igrowlaser.com) in South Korea, Thailand, Singapore,
November 13, 2015 17:25
In New Study EMMA™ Capnograph Has Comparable Accuracy to Sidestream Capnography Against Gold-Standard Blood Gas Analysis
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that in a new study that compared the end tidal carbon dioxide values (EtCO2) from both the Masimo EMMA capnograph and a conventional sidestream
November 12, 2015 14:25
Replicor Announces Publication of Its Pre-Clinical Data on the Therapeutic Effect of NAPs on Hepatitis B Virus Infection.
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the
November 12, 2015 13:35
Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced today at its R&D press conference in Berlin. The c
November 11, 2015 10:55
Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226, https://goo.gl/gUgvqd) of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira
November 11, 2015 10:40
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel dise
November 10, 2015 18:25
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
Brigham and Women’s Hospital in Boston, U.S., and Boehringer Ingelheim announce the results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa® (dabiga
November 10, 2015 17:15
Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
Boehringer Ingelheim announces results from two new analyses evaluating idarucizumab, recently approved under the Accelerated Approval pathway and marketed in the U. S. as Praxbind®, a specific revers
November 10, 2015 14:00
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New sub-analysis data presented today show the reduction in risk for hospitalisation for heart failure or cardiovascular (CV) death with Jardiance®, compared with placebo when added to standard of car
November 10, 2015 10:55
Quintiles Contributes Open Source Code to ResearchKit
Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to g
November 09, 2015 22:00
Replicor Announces Grant of US Patents on HBV / HDV Treatment Methods Combining HBsAg Reduction and Immunotherapy
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces all
November 09, 2015 13:25
EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
Boehringer Ingelheim and Eli Lilly and Company today announced that top-line renal results from the EMPA-REG OUTCOME® study (compound empagliflozin, marketed under the name Jardiance®) will be present
November 09, 2015 11:10
Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502, http://goo.gl/eX9kbP) today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society o
November 06, 2015 13:55
Founder Dennis Gillings to Retire as Quintiles Executive Chairman at Close of 2015
Quintiles Founder Dr. Dennis Gillings, CBE, will retire from his position as Executive Chairman of Quintiles Transnational Holdings Inc. (NYSE: Q) at the end of this year, December 31, 2015. Dr. Gilli
November 06, 2015 13:30
Research Finds Cranberries are an Effective Approach to Help Reduce Antibiotic Use
An international team of scientists presented new evidence showing how cranberries are poised to be a compelling tool to help reduce antibiotic resistance and oxidative stress. This Smart News Rele
November 05, 2015 14:00
Cell Signaling Technology Announces the Release of 6 New Monoclonal Antibodies for Tumor Immunology Research.
Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at
November 05, 2015 13:10
Pharco Pharmaceuticals, Inc. Announces Late-Breaker Oral Presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2015
Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, will present advanced results of
November 05, 2015 12:10
Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanc
November 05, 2015 10:45
Singapore General Hospital and Thermo Fisher Scientific Collaborate to Identify the Prevalence of Asian-Specific Genetic Mutations in Cancer
Singapore General Hospital (SGH) and Thermo Fisher Scientific today announced the establishment of a collaborative partnership that will work to identify cancer genetic mutations linked with Asian pop
25 per page50 per page75 per page100 per page